Introduction: Inversion of the CD4:CD8 ratio ( B1) has been identified as a hallmark of immunosenescence and an independent predictor of mortality in the general population. We aimed to assess the association between the CD4:CD8 ratio and intimamedia thickness (IMT) progression in treated HIV-infected patients as a marker of early atherosclerosis. Materials and Methods: A longitudinal study during three years was conducted in 120 HIV-infected patients receiving antiretroviral treatment (ART). We analyzed the associations between the CD4:CD8 ratio, cardiovascular risk factor and antiretroviral (ARV) treatment and progression of subclinical atherosclerosis assessed using carotid IMT at baseline and after three years. Results: Finally, 96 patients completed the study. Seventy-six (79.1%) patients were male, aged 44910 years, 39 (40.6%) were on treatment with Protease inhibitors, 49 (51.04%) with non-nucleoside reverse transcriptase inhibitors (NNRTI), 6 (6.25%) with integrase inhibitors, 3 (3.12%) with maraviroc and 2 (2.08%) only with nucleoside reverse transcriptase inhibitors (NRTI). The mean of ARV exposition was 6.995.9 years. Twenty six (27 %) patients had family history of ischemic heart disease, 51 (53.12%) were smokers, 12 (12.5%) hypertensive, 4 (4.16%) type 2 diabetes, 23 (23.9%) with dyslipidemia and 31 (32.3%) were infected with C hepatitis virus. Baseline IMT was significantly associated with age (rho 00.497; pB0.001), basal glucemia (rho 00.323; p00.001), triglycerides (rho 00.232; p00.023), Framingham score (rho 00.324; p 00.001), CD4:CD8 ratio (rho 0(0.176; p00.05) and dyslipidemia (0.7290.16 mm vs 0.6390.11 mm; p 00.029). In multivariable analysis where cardiovascular risk factor and ARV were included, IMT progression was inversely associated with CD4:CD8 ratio (OR 00.283; CI 95% 0.099Á0.809; p00.019) and treatment with NNRTI (OR 00.283; CI 95% 0.099Á0.809; p 00.019). Conclusions: The inversion of CD4:CD8 ratio in treated HIV-infected patients is independently associated with IMT progression, a marker of age-associated disease. Therefore, it might be clinically useful as predictor of cardiovascular events. Surprisingly, there was a positive correlation between receiving NNRTI and progression of IMT.
